Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Inflammatory CNV
NCT02556229Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2016
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in choroidal neovascularization (CNV), sponsored by Hospices Civils de Lyon. Started Jun 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02556229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556229.